# Biocryst Pharmaceuticals Inc: financial statements, quarterly

BCRX · Nasdaq · CIK 882796 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bcrx.md) · [Financials](/companies/bcrx/financials.md) · [Filings](/companies/bcrx/filings.md) · [Insiders](/companies/bcrx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bcrx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [86.7](/filings/0001628280-24-045364.md) | [93.4 d](/filings/0001628280-26-012240.md) | [92.8](/filings/0001628280-25-022658.md) | [109](/filings/0001628280-25-037795.md) | [117](/filings/0001628280-25-048785.md) | [132 d](/filings/0001628280-26-012240.md) | [146](/filings/0001628280-26-031238.md) | [163](/filings/0001628280-26-053300.md) | [159](/filings/0001628280-25-048785.md) | [407 d](/filings/0001628280-26-012240.md) | [156](/filings/0001628280-26-031238.md) | [218](/filings/0001628280-26-053300.md) |
| Cost of revenue | $m | [1.1](/filings/0001628280-24-045364.md) | [1.6 d](/filings/0001628280-26-012240.md) | [1.3](/filings/0001628280-25-022658.md) | [1.7](/filings/0001628280-25-037795.md) | [3.2](/filings/0001628280-25-048785.md) | [6.1 d](/filings/0001628280-26-012240.md) | [4.6](/filings/0001628280-26-031238.md) | [2.8](/filings/0001628280-26-053300.md) | [2.2](/filings/0001628280-25-048785.md) | [9.5 d](/filings/0001628280-26-012240.md) | [5.4](/filings/0001628280-26-031238.md) | [3.8](/filings/0001628280-26-053300.md) |
| Research and development | $m | [46.9](/filings/0001628280-24-045364.md) | [70.1 d](/filings/0001628280-26-012240.md) | [46.5](/filings/0001628280-25-022658.md) | [37.6](/filings/0001628280-25-037795.md) | [41.1](/filings/0001628280-25-048785.md) | [49.4 d](/filings/0001628280-26-012240.md) | [37.3](/filings/0001628280-26-031238.md) | [43.4](/filings/0001628280-26-053300.md) | [44.6](/filings/0001628280-25-048785.md) | [40.9 d](/filings/0001628280-26-012240.md) | [60.3](/filings/0001628280-26-031238.md) | [52.0](/filings/0001628280-26-053300.md) |
| Selling, general and administrative | $m | [50.6](/filings/0001628280-24-045364.md) | [64.6 d](/filings/0001628280-26-012240.md) | [59.5](/filings/0001628280-25-022658.md) | [61.2](/filings/0001628280-25-037795.md) | [65.1](/filings/0001628280-25-048785.md) | [80.5 d](/filings/0001628280-26-012240.md) | [82.5](/filings/0001628280-26-031238.md) | [87.4](/filings/0001628280-26-053300.md) | [83.0](/filings/0001628280-25-048785.md) | [95.8 d](/filings/0001628280-26-012240.md) | [94.6](/filings/0001628280-26-031238.md) | [64.0](/filings/0001628280-26-053300.md) |
| Operating income | $m | [(11.9)](/filings/0001628280-24-045364.md) | [(42.7) d](/filings/0001628280-26-012240.md) | [(14.5)](/filings/0001628280-25-022658.md) | [8.8](/filings/0001628280-25-037795.md) | [7.7](/filings/0001628280-25-048785.md) | [(4.5) d](/filings/0001628280-26-012240.md) | [21.2](/filings/0001628280-26-031238.md) | [29.8](/filings/0001628280-26-053300.md) | [29.6](/filings/0001628280-25-048785.md) | [260 d](/filings/0001628280-26-012240.md) | [(702)](/filings/0001628280-26-031238.md) | [98.5](/filings/0001628280-26-053300.md) |
| Interest expense | $m | [27.3](/filings/0001628280-23-037847.md) | [24.6 d](/filings/0001628280-24-007205.md) | [24.5](/filings/0001628280-24-021069.md) | [24.7](/filings/0001628280-24-035170.md) | [24.8](/filings/0001628280-25-048785.md) | [24.4 d](/filings/0001628280-26-012240.md) | [23.5](/filings/0001628280-26-031238.md) | [21.6](/filings/0001628280-26-053300.md) | [19.7](/filings/0001628280-25-048785.md) | [14.1 d](/filings/0001628280-26-012240.md) | [19.8](/filings/0001628280-26-031238.md) | [21.7](/filings/0001628280-26-053300.md) |
| Income tax | $m | [0.3](/filings/0001628280-24-045364.md) | [(1.4) d](/filings/0001628280-26-012240.md) | [0.4](/filings/0001628280-25-022658.md) | [0.2](/filings/0001628280-25-037795.md) | [0.6](/filings/0001628280-25-048785.md) | [0.8 d](/filings/0001628280-26-012240.md) | [0.7](/filings/0001628280-26-031238.md) | [1.4](/filings/0001628280-26-053300.md) | [(0.8)](/filings/0001628280-25-048785.md) | [2.2 d](/filings/0001628280-26-012240.md) | [1.0](/filings/0001628280-26-031238.md) | [1.1](/filings/0001628280-26-053300.md) |
| Net income | $m | [(36.1)](/filings/0001628280-24-045364.md) | [(61.7) d](/filings/0001628280-26-012240.md) | [(35.4)](/filings/0001628280-25-048785.md) | [(12.7)](/filings/0001628280-25-048785.md) | [(14.0)](/filings/0001628280-25-048785.md) | [(26.8) d](/filings/0001628280-26-012240.md) | [0.0](/filings/0001628280-26-053300.md) | [5.1](/filings/0001628280-26-053300.md) | [12.9](/filings/0001628280-25-048785.md) | [246 d](/filings/0001628280-26-012240.md) | [(722)](/filings/0001628280-26-053300.md) | [78.4](/filings/0001628280-26-053300.md) |
| Diluted EPS | $ per share | [(0.19)](/filings/0001628280-24-045364.md) | not reported | [(0.17)](/filings/0001628280-25-022658.md) | [(0.06)](/filings/0001628280-25-037795.md) | [(0.07)](/filings/0001628280-25-048785.md) | not reported | [0.00](/filings/0001628280-26-031238.md) | [0.02](/filings/0001628280-26-053300.md) | [0.06](/filings/0001628280-25-048785.md) | not reported | [(2.98)](/filings/0001628280-26-031238.md) | [0.30](/filings/0001628280-26-053300.md) |
| Basic EPS | $ per share | [(0.19)](/filings/0001628280-24-045364.md) | not reported | [(0.17)](/filings/0001628280-25-022658.md) | [(0.06)](/filings/0001628280-25-037795.md) | [(0.07)](/filings/0001628280-25-048785.md) | not reported | [0.00](/filings/0001628280-26-031238.md) | [0.02](/filings/0001628280-26-053300.md) | [0.06](/filings/0001628280-25-048785.md) | not reported | [(2.98)](/filings/0001628280-26-031238.md) | [0.31](/filings/0001628280-26-053300.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [151](/filings/0001628280-23-037847.md) | [111](/filings/0001628280-26-012240.md) | [84.3](/filings/0001628280-25-022658.md) | [78.4](/filings/0001628280-25-037795.md) | [96.8](/filings/0001628280-25-048785.md) | [105](/filings/0001628280-26-012240.md) | [105](/filings/0001628280-26-031238.md) | [88.0](/filings/0001628280-26-053300.md) | [84.1](/filings/0001628280-25-048785.md) | [89.7](/filings/0001628280-26-053300.md) | [172](/filings/0001628280-26-031238.md) | [155](/filings/0001628280-26-053300.md) |
| Current assets | $m | [502](/filings/0001628280-23-037847.md) | [496](/filings/0001628280-25-007715.md) | [447](/filings/0001628280-24-021069.md) | [363](/filings/0001628280-24-035170.md) | [427](/filings/0001628280-24-045364.md) | [422](/filings/0001628280-26-012240.md) | [410](/filings/0001628280-25-022658.md) | [398](/filings/0001628280-25-037795.md) | [356](/filings/0001628280-25-048785.md) | [404](/filings/0001628280-26-053300.md) | [374](/filings/0001628280-26-031238.md) | [485](/filings/0001628280-26-053300.md) |
| Total assets | $m | [523](/filings/0001628280-23-037847.md) | [517](/filings/0001628280-25-007715.md) | [468](/filings/0001628280-24-021069.md) | [472](/filings/0001628280-24-035170.md) | [491](/filings/0001628280-24-045364.md) | [490](/filings/0001628280-26-012240.md) | [480](/filings/0001628280-25-022658.md) | [457](/filings/0001628280-25-037795.md) | [446](/filings/0001628280-25-048785.md) | [514](/filings/0001628280-26-053300.md) | [465](/filings/0001628280-26-031238.md) | [558](/filings/0001628280-26-053300.md) |
| Current liabilities | $m | [90.8](/filings/0001628280-23-037847.md) | [150](/filings/0001628280-25-007715.md) | [120](/filings/0001628280-24-021069.md) | [129](/filings/0001628280-24-035170.md) | [154](/filings/0001628280-24-045364.md) | [160](/filings/0001628280-26-012240.md) | [140](/filings/0001628280-25-022658.md) | [177](/filings/0001628280-25-037795.md) | [190](/filings/0001628280-25-048785.md) | [196](/filings/0001628280-26-053300.md) | [195](/filings/0001628280-26-031238.md) | [209](/filings/0001628280-26-053300.md) |
| Total liabilities | $m | not reported | [972](/filings/0001628280-25-007715.md) | not reported | not reported | [960](/filings/0001628280-24-045364.md) | [966](/filings/0001628280-26-012240.md) | [932](/filings/0001628280-25-022658.md) | [879](/filings/0001628280-25-037795.md) | [834](/filings/0001628280-25-048785.md) | [633](/filings/0001628280-26-053300.md) | [1,019](/filings/0001628280-26-031238.md) | [1,012](/filings/0001628280-26-053300.md) |
| Long-term debt | $m | [298](/filings/0001628280-23-037847.md) | [303](/filings/0001628280-25-007715.md) | [308](/filings/0001628280-24-021069.md) | [314](/filings/0001628280-24-035170.md) | [314](/filings/0001628280-24-045364.md) | [315](/filings/0001628280-26-012240.md) | [315](/filings/0001628280-25-022658.md) | [243](/filings/0001628280-25-037795.md) | [194](/filings/0001628280-25-048785.md) | [0.0](/filings/0001628280-26-053300.md) | [395](/filings/0001628280-26-031238.md) | [395](/filings/0001628280-26-053300.md) |
| Shareholders' equity | $m | [(411)](/filings/0001628280-24-045364.md) | [(456)](/filings/0001628280-26-012240.md) | [(476)](/filings/0001628280-25-048785.md) | [(476)](/filings/0001628280-25-048785.md) | [(469)](/filings/0001628280-25-048785.md) | [(476)](/filings/0001628280-26-053300.md) | [(452)](/filings/0001628280-26-053300.md) | [(422)](/filings/0001628280-26-053300.md) | [(388)](/filings/0001628280-25-048785.md) | [(119)](/filings/0001628280-26-053300.md) | [(554)](/filings/0001628280-26-053300.md) | [(454)](/filings/0001628280-26-053300.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(19.9) d](/filings/0001628280-24-045364.md) | [(8.9) d](/filings/0001628280-26-012240.md) | [(53.7)](/filings/0001628280-25-022658.md) | [(1.4) d](/filings/0001628280-25-037795.md) | [8.2 d](/filings/0001628280-25-048785.md) | [(5.2) d](/filings/0001628280-26-012240.md) | [(27.5)](/filings/0001628280-26-031238.md) | [41.3 d](/filings/0001628280-26-053300.md) | [41.6 d](/filings/0001628280-25-048785.md) | [292 d](/filings/0001628280-26-012240.md) | [(61.8)](/filings/0001628280-26-031238.md) | [104 d](/filings/0001628280-26-053300.md) |
| Capital expenditure | $m | [1.0 d](/filings/0001628280-24-045364.md) | [0.6 d](/filings/0001628280-26-012240.md) | [0.2](/filings/0001628280-25-022658.md) | [0.2 d](/filings/0001628280-25-037795.md) | [0.1 d](/filings/0001628280-25-048785.md) | [0.7 d](/filings/0001628280-26-012240.md) | [0.1](/filings/0001628280-26-031238.md) | [0.2 d](/filings/0001628280-26-053300.md) | [1.3 d](/filings/0001628280-25-048785.md) | [0.8 d](/filings/0001628280-26-012240.md) | [0.4](/filings/0001628280-26-031238.md) | [0.2 d](/filings/0001628280-26-053300.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [186](/filings/0001628280-23-037847.md) | [189](/filings/0001628280-24-021069.md) | [189](/filings/0001628280-24-035170.md) | [190](/filings/0001628280-24-045364.md) | [206](/filings/0001628280-25-022658.md) | [206](/filings/0001628280-25-037795.md) | [207](/filings/0001628280-25-048785.md) | [215](/filings/0001628280-26-031238.md) | [220](/filings/0001628280-26-053300.md) | [220](/filings/0001628280-25-048785.md) | [242](/filings/0001628280-26-031238.md) | [265](/filings/0001628280-26-053300.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 255,535,105 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001628280-26-053300.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:27 ET. No prices; not investment advice.